Research dossier
BPC-157 — cell migration and the FAK pathway dossier
A sequence derived from a gastric juice protein, widely studied in cell migration models.
Translated from the French original, which remains the reference version: lire en français →
Molecular identity
| Parameter | Value |
|---|---|
| CAS number | 137525-51-0 |
| Molar mass | 1419.55 g/mol |
| Molecular formula | C₆₂H₉₈N₁₆O₂₂ |
| Sequence / nature | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Purity | ≥99% |
| Appearance | White lyophilised powder |
The values above correspond to the catalogue lot and are reproduced as they stand from the product page. Any discrepancy between this dossier and the product page should be reported before use.
Research context
This peptide occupies a particular position: heavily studied in preclinical models, very little in controlled clinical studies, and discussed at length outside the scientific field. That gap between the volume of discussion and the volume of evidence makes a critical reading of the literature all the more necessary. In the laboratory, its interest lies in cell migration models, where it frequently serves as a comparison compound.
Mechanism studied
BPC-157 is a pentadecapeptide whose sequence corresponds to a portion of a protective protein identified in human gastric juice. It is not an isolated native molecule but a synthetic fragment reproduced by solid-phase peptide synthesis.
The in-vitro literature has mainly examined its interaction with the FAK–paxillin signalling pathway, involved in the assembly of focal adhesions and therefore in the ability of cells to adhere to a substrate and migrate. Work in culture has measured the migration of fibroblasts and endothelial cells in the presence of the peptide, by scratch assay and in a Boyden chamber.
A second line described concerns expression of the VEGFR2 receptor and the formation of tubular structures in three-dimensional matrix — standard models for studying angiogenesis in vitro. The literature also refers to modulation of the nitric oxide axis, measured by nitrite assay in the culture supernatant.
In-vitro literature
The published body of work is mostly preclinical and in-vitro. The models most frequently reported are cell migration assays, gene expression measurement by RT-qPCR on extracellular matrix markers, and tube formation models on matrix. The stability of the peptide in acidic media receives particular methodological attention, because it governs the validity of prolonged exposure protocols.
Bibliographic entry points
- PubMed — peer-reviewed literature
- PubChem — chemical profile and assay data
- NCBI — methodology and receptor references
These links are an entry point into the literature, not an edited selection. None of the sources cited relates to a human use of this material, and consulting them directly is recommended for any protocol design.
Distinguishing this compound from its analogues
BPC-157 in acetate form and in arginate form do not have the same solubility or the same stability in solution. The form supplied must be checked: it determines the reconstitution protocol and the chromatographic behaviour.
The CAS number shown on the product page is the identifier to rely on. Trade names, development codes and customary abbreviations vary from one source to another and are not a reliable identification.
Effects reported in the experimental literature
The published work on BPC-157 is overwhelmingly preclinical: in-vitro cell models and animal models, mainly rodents. That documentary base determines what can and cannot be said about the compound.
What is sometimes presented as the “benefits” of BPC-157 corresponds, in the publications, to experimental observations in models. The effects described in that literature concern fibroblast migration, angiogenesis and expression of the FAK-paxillin pathway, in models of tissue injury. These observations are experimental results in models, not effects established in humans.
What the evidence base does not contain
No published phase 3 clinical trial. The compound has not passed through the evaluation stages that would allow a benefit-risk balance to be established in humans.
No marketing authorisation, in any jurisdiction.
No characterised human side-effect profile. The absence of adverse effects reported in animal models is not a demonstration of safety in humans: it is an absence of data, which is a different thing.
That last distinction is the one most often lost. A favourable preclinical literature and a non-existent clinical literature do not add up to a presumption of safety.
The material offered on this site is an analytical standard intended exclusively for in-vitro research. What we document about it concerns lot analysis — identity, purity, content — and nothing else.
Methodological limits
The body of work is almost exclusively preclinical and concentrated among a small number of teams, which limits the robustness of independent replication. Protocols vary considerably in the concentration used and the culture medium, and scratch assays are sensitive to the initial cell density — a variable rarely reported precisely.
These limits are not formalities: they determine what a protocol using this material can and cannot establish. Making them explicit in the experimental plan avoids attributing to the compound an observation that belongs to the measurement system.
Analytical parameters
A short sequence, with no disulfide bridge, which simplifies reading the chromatogram. The expected impurities are mainly truncated sequences from the synthesis, resolved on a standard RP-HPLC gradient.
| Parameter | Value |
|---|---|
| Storage | Store at −20 °C, protected from light |
| Solubility | Soluble in bacteriostatic water (BAC) |
| Stability | Stable for 24 months at −20 °C; 30 days after reconstitution at 2–8 °C |
| Control methods | RP-HPLC · MS · NMR |
Reconstitution is a matter for the experimental protocol. The volume of solvent determines the final concentration and is not prescribed here: it depends on the design of the experiment and the conditions of the assay.
Resulting concentrations
The table below is arithmetic: it gives the concentration obtained for a given solvent volume, with no recommendation of use.
| Format | 1 ml | 2 ml | 3 ml |
|---|---|---|---|
| 10mg | 10.00 mg/ml | 5.00 mg/ml | 3.33 mg/ml |
These values assume complete dissolution and a peptide content consistent with the lot report. Where the actual quantitative content differs from the nominal mass — a common discrepancy, caused by counter-ions and residual water — the effective concentration is lower than the theoretical value. That is precisely why quantitative content per vial forms part of the verification protocol.
Protocol design
Three points govern the validity of an assay using this material, whatever the question being asked.
The effective concentration is not the nominal concentration. It depends on the actual peptide content of the lot, on complete dissolution and on adsorption to the walls of the container. A concentration check after reconstitution is preferable to assuming a perfect yield.
The actual exposure time may be shorter than the nominal duration where the compound is degraded by the medium. Verify stability under the exact conditions of the assay — medium, serum, temperature, duration — before interpreting an absence of effect.
The control arm must correspond to the vehicle actually used, at the same final concentration. This requirement is unremarkable and remains the most frequent cause of irreproducible results.
Lot verification
The following formats are covered by a Janoshik Analytical report, readable from the product page:
- 10mg — lot report available
| Format | Lot report | Availability |
|---|---|---|
| 10mg | Covered | In stock |
The verification programme covers exclusively the identity and purity of the material, by reversed-phase chromatography and mass spectrometry. It covers neither sterility, nor endotoxins, nor any microbiological characteristic.
Frequently asked questions
How does this product arrive?
As a lyophilised powder in a sealed vial, shipped in insulated, plain packaging. Return the vial to the storage temperature given in the specifications on receipt.
Which solvent should be used for reconstitution?
Bacteriostatic water is the usual reconstitution solvent for lyophilised peptides in a laboratory setting. The volume is a matter for the experimental protocol and the concentration sought; we provide no dosage recommendation.
How long does the material remain stable?
The stability window appears in the specifications table on this page, before and after reconstitution. Those values correspond to the storage conditions stated; any temperature variation shortens them.
Does the analysis report correspond exactly to my vial?
The report linked on this page corresponds to the format selected. Each report is issued by Janoshik Analytical from an anonymously submitted sample, and covers the identity and purity of the peptide.
Can this product be used on humans or animals?
No. It is an analytical grade reference material intended exclusively for in-vitro laboratory research. Any administration to humans or animals is excluded, and no therapeutic, diagnostic or medical claim is made.
See also: BPC-157 or TB-500: the comparison